Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

4.14
-0.0900-2.13%
Post-market: 4.150.0050+0.12%17:04 EDT
Volume:758.70K
Turnover:3.17M
Market Cap:129.54M
PE:-1.00
High:4.29
Open:4.23
Low:4.12
Close:4.23
52wk High:50.40
52wk Low:4.12
Shares:31.29M
Float Shares:18.39M
Volume Ratio:0.99
T/O Rate:4.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.59
PE(LYR):-1.45

Loading ...

Sangamo Therapeutics Completes Key Technology Asset Sale

TIPRANKS
·
Sep 09

Keros Therapeutics announces $5M share repurchase program after Takeda payment

TIPRANKS
·
Sep 09

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewswire
·
Sep 09

CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

GlobeNewswire
·
Sep 09

Press Release: Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million

Dow Jones
·
Sep 09

ME Therapeutics Advances Dual-Target CAR and STING mRNA Programs as NASDAQ Plans Progress

TIPRANKS
·
Sep 09

Shares of Beam Therapeutics Retreat After Updated Trial Data Disappoints

Dow Jones
·
Sep 09

enGene Therapeutics Price Target Maintained with a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 09

Beam Therapeutics: Buy Rating Reiterated as BEAM-302 Data Strengthens Clinical Profile; $80 Price Target Maintained

TIPRANKS
·
Sep 09

TScan Therapeutics Cut to Neutral from Buy by HC Wainwright & Co.

Dow Jones
·
Sep 08

Beam Therapeutics: Buy Rating Backed by Strengthened BEAM-302 Clinical Profile and Clearer Accelerated Approval Path Despite Market Pullback

TIPRANKS
·
Sep 08

Beam Therapeutics falls -12.7%

TIPRANKS
·
Sep 08

Spyre Therapeutics' SPY003 Meets Phase 2 Primary Endpoint in Ulcerative Colitis

MT Newswires Live
·
Sep 08

Lokahi Therapeutics expands ai2 platform into three business divisions

TIPRANKS
·
Sep 08

Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums

GlobeNewswire
·
Sep 08

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

TIPRANKS
·
Sep 08

Relmada Therapeutics Announces Urology Chief Medical Officer Exit

TIPRANKS
·
Sep 08

Spyre Therapeutics Reports Positive Phase 2 SKYLINE Data

TIPRANKS
·
Sep 08

Tvardi Therapeutics Price Target Announced at $14.00/Share by LUCID Capital Markets

Dow Jones
·
Sep 08

Spyre Therapeutics announces 12-week induction data from Part A of SKYLINE trial

TIPRANKS
·
Sep 08